Silo Pharma closes $4 million private placement priced at-the-market

Silo Pharma, Inc. (Nasdaq: SILO) entered securities purchase agreements on July 9, 2026 with institutional investors for the issuance and sale of 124,000 shares of common stock at $6.452 per share, pre-funded warrants to purchase up to 495,965 shares at $6.4519 per pre-funded warrant, Series A-3 warrants to purchase up to 619,965 shares, and Series A-4 warrants to purchase up to 619,965 shares.¹

Each warrant carries an exercise price of $6.21 per share and is exercisable immediately upon issuance.¹ The Series A-3 warrants expire five years after the effective date of the Resale Registration Statement, while the Series A-4 warrants expire eighteen months after that date.¹

The private placement closed on July 10, 2026.¹ Net proceeds to the company are expected to be approximately $3.5 million after deducting placement agent fees, expenses, and estimated offering expenses.¹ The company intends to use the net proceeds for working capital and general corporate purposes.¹

H.C. Wainwright & Co. acted as exclusive placement agent for the offering.¹ As compensation, the company paid Wainwright a cash fee of 7.5% of gross proceeds plus a 1.0% management fee, and issued placement agent warrants for up to 46,497 shares at an exercise price of $8.065 per share.¹

Under a related registration rights agreement dated July 9, 2026, the company agreed to file a resale registration statement covering the shares and warrant shares within 15 days, aiming for effectiveness within 30 days (or 60 days if the SEC conducts a full review).¹

A related Form D filing showed total offering amount and total amount sold both listed as $4,000,015, with $0 remaining to be sold.² Four investors participated in the offering.²